BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mirador Biomedical to Learn Soon if FDA Approves New Pressure Sensor Device for Catherter Injections


10/12/2010 7:15:31 AM

Puget Sound Business Journal (Seattle) - by Clay Holtzman

This week, Seattle medical device company Mirador Biomedical is expected to learn whether the Food & Drug Administration has approved its new pressure sensor device for catheter injections.

Company CEO Karl Schmidt says he expects to hear back from the FDA soon. On Wednesday, it will be 90 days since Mirador filed its 510(k) application with the FDA, which states that it aims to get back to applicants within 90 days of filing. Schmidt said he doesn’t expect there to be any major problems with the device.

“We don’t anticipate us having to make any serious design changes,” Schmidt said. Mirador submitted its application in March of this year; the review process takes about 90 days.

The Compass Vascular Access device attaches to a needle and measures pressure of blood flow at the point of insertion, which is displayed in a digital gauge. The device can identify whether the needle used to insert a catheter is puncturing a vein or an artery. If approved, the sensors will cost between $20 and $50 apiece.

Mirador is preparing 1,500 units ahead of the FDA decision, but it is capable of producing between 50,000 and 100,000 units a year, Schmidt said.Schmidt says Mirador has been talking with 10 hospitals that are interested in using the device, while a dozen of them want to test it.

The co-director of emergency medicine research at Seattle Children’s Research Institute, Julie Brown, plans to test the Compass device for its secondary application: lumbar (back) injections in children. That research is funded by a $150,000 grant from the Washington State Life Sciences Discovery Fund.Schmidt said that on the high end, his company’s device could sell into a market worth about $200 million a year.

If the Compass device is approved, Mirador could get an early jump on putting the device in front of potential clients. The company will be attending the annual meeting of the American Society of Anesthesiologists from Oct. 16-20 in San Diego.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES